|

Semaglutide Clinical Trials

25 actively recruiting trials across 11 locations

▲ +2 trials since May 2026

Also known as: Ozempic, Rybelsus, Wegovy

Pipeline

Phase 1: 3Phase 2: 8Phase 3: 6Phase 4: 4Phase 1/2: 1

Top Sponsors

  • Novo Nordisk A/S4
  • Chinese Academy of Sciences2
  • University of Washington1
  • University of Chicago1
  • University Medical Centre Ljubljana1

Indications

Other14 trials

A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
Phase 1
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
Phase 3
A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Phase 2
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Phase 1
COMMETS- Combination MCI Metabolic Syndrome
Phase 2
Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
Phase 2
GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM
Phase 4
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
Phase 3
Probiotic Intervention on Body Weight
N/A
Protein Supplementation Intervention on Body Weight
N/A
Semaglutide for Smoking Cessation in Patients With Diabetes
Phase 3
Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes
N/A
The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
Phase 4
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
Phase 1

Birmingham, Alabama1 trial

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

Uni of Alabama at Birmingham

Phase 3

Glendale, Arizona1 trial

Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Kailera Clinical Site

Phase 3

Phoenix, Arizona1 trial

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

The University of Arizona College of Medicine- Phoenix

Phase 3

Duarte, California1 trial

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

City of Hope Medical Center

Phase 2

Lancaster, California1 trial

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

First Valley Medical Group

Phase 2

Palo Alto, California1 trial

Mechanisms of Semaglutide Therapy in Heart Failure Patients

Greenstone Biosciences

Phase 1/2

San Dimas, California1 trial

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

N America Res Inst - San Dimas

Phase 2

Aurora, Colorado1 trial

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

University of Colorado Anschutz Medical Campus

Phase 2

Bethesda, Maryland1 trial

Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

National Institutes of Health Clinical Center

Phase 2

Rochester, Minnesota1 trial

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

Mayo Clinic

Phase 4

Brownsville, Texas1 trial

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

UTHealth Clinical Research Unit (CRU) at UT Brownsville

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.